Sign in

Private company

Sigilon Therapeutics, Inc.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2023 annual report the company says: “We are a preclinical stage biotechnology company pioneering a new class of therapeutics and seeking to develop functional cures for patients with acute and chronic diseases by providing stable and durable levels of therapeutic molecules to patients.”42 It is headquartered in Cambridge, Massachusetts.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersCambridge, Massachusetts1
  • Incorporated inDE2
  • Business address100 Binney Street, Ste 600, Cambridge, Ma 021422
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-337.3%Operating margin3
-336.8%Net margin4
34.8%Revenue growth, 20223
-111.4%Return on equity3
0.31×Debt to equity3
-$52.0MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development94¢$37.6M
  • Interest6¢$2.3M

Out of $12.9M in revenue.34 The company lost money this year.

Financial statements

Revenue53$12.9M in 2022−3% since 2020
0$5.0M$10.0M$15.0M2020: $13.4M$13.4M20202021: $9.6M$9.6M2021−28%2022: $12.9M$12.9M2022+35%
Operating income53-$43.7M in 2022−17% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$52.6M-$52.6M20202021: -$75.6M-$75.6M2021+44%2022: -$43.7M-$43.7M2022−42%
Net income534-$43.6M in 2022−20% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$54.6M-$54.6M20202021: -$77.3M-$77.3M2021+42%2022: -$43.6M-$43.6M2022−44%
Fiscal year2019202020212022
Revenue$13.4M5$9.6M3$12.9M3
Research and development$53.5M5$65.1M3$37.6M3
Operating expenses$85.2M3$56.6M3
Operating income-$52.6M5-$75.6M3-$43.7M3
Interest$1.2M5$2.0M3$2.3M3
Income tax$05$03$03
Net income-$54.6M5-$77.3M3-$43.6M4
Earnings per share-$7.555-$2.433-$1.343
Earnings per share (diluted)-$7.555-$2.433-$1.343
Shares (weighted, basic)31.9M shares332.4M shares3
Shares (weighted, diluted)31.9M shares332.4M shares3

Compare Sigilon Therapeutics, Inc. with another company

Corporate structure

Sigilon Therapeutics, Inc. is part of a group headed by Eli Lilly and Company. 163 entities, 54 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Sigilon Therapeutics, Inc.

  • Flagship Ventures Fund V, L.P. Filed SC 13G/A on Sigilon Therapeutics, Inc., latest Feb 14, 2024
  • BlackRock Filed SC 13G on Sigilon Therapeutics, Inc., latest Jul 8, 2022 (2 filings since Feb 4, 2022)
  • Eli Lilly and Company Indianapolis, Indiana, United States
    • Sigilon Therapeutics, Inc. Cambridge, Massachusetts
    • Eli Lilly (India) Subsidiary · Gurgaon, India
    • Eli Lilly (United Kingdom) Subsidiary · Basingstoke, United Kingdom
    • ImClone Systems Subsidiary
    • Lilly (China) Subsidiary · Shanghai, People's Republic of China
    • Lilly France Subsidiary · Neuilly-sur-Seine, France
    • Adverum Biotechnologies, Inc. Subsidiary · Delaware, United States
    • Adverum NC, LLC Subsidiary · Delaware, United States
    • Akouos, Inc. Subsidiary · Delaware, United States
    • Alnara Pharmaceuticals, Inc. Subsidiary · Delaware, United States
    • Annapurna Therapeutics, Ltd. Subsidiary · Ireland
    • Aparito Espanya S.L. Subsidiary · Spain
    • Aparito LLC Subsidiary · Delaware, United States
    • ARMO Biosciences, Inc. Subsidiary · Delaware, United States
    • Avalanche Australia Pty Ltd. Subsidiary · Australia
    • Avid Radiopharmaceuticals, Inc. Subsidiary · Delaware, United States
    • CoLucid Pharmaceuticals, Inc. Subsidiary · Delaware, United States
    • Compania Farmaceutica Eli Lilly de Centro America S.A. Subsidiary · Guatemala
    • CPD 4, Inc. Subsidiary · Delaware, United States
    • Dermira, Inc. Subsidiary · Delaware, United States
    • DICE Alpha Inc. Subsidiary · Delaware, United States
    • DICE Molecules SV, Inc. Subsidiary · Delaware, United States
    • DICE Therapeutics, Inc. Subsidiary · Delaware, United States
    • Disarm Therapeutics Inc. Subsidiary · Delaware, United States
    • Dista Ilac Ticaret Limited Sirketi Subsidiary · Turkey
    • and 138 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Sigilon Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$7.2M3 Dec 31, 2022$7.2M3 Dec 31, 2021+0.3%
Accumulated depreciation$4.3M3 Dec 31, 2022$3.2M3 Dec 31, 2021+36.6%
Property and equipment, net$2.9M3 Dec 31, 2022$4.0M3 Dec 31, 2021−28.5%
Operating-lease assets (leased space)$9.0M3 Dec 31, 2022$12.9M3 Dec 31, 2021−30.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$42.1M3 Dec 31, 2022$107.1M3 Dec 31, 2021−60.7%
Marketable securities, current$27.6M3 Dec 31, 2022$16.2M3 Dec 31, 2021+70.0%
Debt securities available for sale$27.6M3 Dec 31, 2022$16.2M3 Dec 31, 2021+70.0%

Leadership

Who has led Sigilon Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Coelho Rogerio Vivaldi2020–2023

President

  1. Coelho Rogerio Vivaldi2020–2023

Chief financial officer

  1. Glenn Reicin2020–2021
  2. Josias Pontes2022–2023

Chief operating officer

  1. Devyn Smith2020–2021
2025
Board members and other officers (13)

Timeline

  1. Aug 11, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights23
  2. Jun 29, 20238-K Entered a material agreement; Other events24
  3. May 22, 20238-K Ended a material agreement; Bylaws or fiscal year changed; Shareholder vote25
  4. May 9, 20238-K Results of operations26
  5. Mar 14, 20238-K Results of operations; Regulation FD disclosure27
  6. Mar 10, 20238-K Regulation FD disclosure28
  7. Feb 28, 20238-K Other events29
  8. Feb 13, 20238-K Executive or director change30
  9. Dec 21, 20228-K Listing notice or transfer31
  10. Nov 10, 20228-K Results of operations; Regulation FD disclosure32
  11. Oct 11, 20228-K Regulation FD disclosure33
  12. Sep 26, 20228-K Executive or director change34
  13. Dec 3, 2020New chief executive Coelho Rogerio Vivaldi becomes CEO7

Calendar

When it reported results

  1. May 9, 2023Reported quarterly or annual results26
  2. Mar 14, 2023Reported quarterly or annual results27
  3. Nov 10, 2022Reported quarterly or annual results32
  4. Aug 4, 2022Reported quarterly or annual results35
  5. May 12, 2022Reported quarterly or annual results36
  6. Mar 14, 2022Reported quarterly or annual results37
  7. Nov 10, 2021Reported quarterly or annual results38

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

105 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 21 major events, 48 insider forms, 5 large holders, 23 other. The latest 20:

  1. Feb 14, 2024SC 13G/A EDGAR
  2. Aug 21, 202315-12G EDGAR
  3. Aug 15, 2023EFFECT EDGAR
  4. Aug 15, 20234 FORM 4 SUBMISSION EDGAR
  5. Aug 14, 2023SC 13D/A EDGAR
  6. Aug 11, 20234 EDGAR
  7. Aug 11, 20234 EDGAR
  8. Aug 11, 20234 EDGAR
  9. Aug 11, 20234 EDGAR
  10. Aug 11, 20234 EDGAR
  11. Aug 11, 20234 EDGAR
  12. Aug 11, 20234 EDGAR
  13. Aug 11, 20234 EDGAR
  14. Aug 11, 20234 EDGAR
  15. Aug 11, 20234 EDGAR
  16. Aug 11, 20234 EDGAR
  17. Aug 11, 2023S-8 POS EDGAR
  18. Aug 11, 2023S-8 POS EDGAR
  19. Aug 11, 2023S-8 POS EDGAR
  20. Aug 11, 2023S-8 POS EDGAR

The 105 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 11, 2023Shenandoah Acquisition CorpBuy1,718,493$14.92$25.6MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Sigilon Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSigilon Therapeutics, Inc.1
  • CIK0001821323
  • Employer ID (EIN)47-40055431
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address100 Binney Street, Ste 600, Cambridge, MA 021421
  • Phone617-336-75401
  • Shares outstanding2,514,498 as of Aug 1, 20234
  • Public float$18.2M as of Jun 30, 20223
  • On EDGAR sinceAug 21, 20201
  • Filings184 in all: 4 (66), 8-K (29), 3 (20), 10-Q (8), CORRESP (4), S-8 (4), S-8 POS (4), SC 13G (4)1
    All 37 form types

    10-K (3), DEF 14A (3), DEFA14A (3), EFFECT (3), SC 14D9/A (3), SC TO-T/A (3), DRS/A (2), DRSLTR (2), SEC STAFF LETTER (2), UPLOAD (2), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), ARS (1), CERT (1), DRS (1), POS AM (1), PRE 14A (1), S-1 (1), S-1/A (1), S-1MEF (1), S-3 (1), SC 13D (1), SC 13D/A (1), SC 13G/A (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 14, 2023
    Quarterly report (10-Q) Aug 7, 2023
    Proxy statement (DEF 14A) Apr 6, 2023
    Latest 8-K (8-K) Aug 11, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42